XM levert geen diensten aan inwoners van de Verenigde Staten.
S
S

Sanofi


Nieuws

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

UPDATE 1-GSK asks to appeal Delaware ruling allowing Zantac cases to go forward Recasts headline, paragraphs 1-4 with appeal petition By Brendan Pierson June 10 (Reuters) - GSK GSK.L and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
G
P
S

Latest trial over Zantac cancer claims called off as plaintiff drops case

Latest trial over Zantac cancer claims called off as plaintiff drops case By Brendan Pierson June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's GSK.L discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced. GSK said in a statement that it did not settle with the woman, Eugenia Kasza.
G
P
S

Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial

BUZZ-Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial ** Shares of Moderna MRNA.O rise 1.81% to $153.75 premarket ** Co says its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response when compared to separate shots in a late-stage trial ** The combination vacci
G
S

Moderna COVID/flu combo vaccine superior to separate shots in trial

Moderna COVID/flu combo vaccine superior to separate shots in trial By Patrick Wingrove June 10 (Reuters) - Moderna MRNA.O said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial. In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna's
S

What to know about bird flu in dairy cows and the risk to humans

EXPLAINER-What to know about bird flu in dairy cows and the risk to humans Adds new details on affected states in paragraphs 1-2, details on a fatal case in Mexico By Julie Steenhuysen CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.
G
S

EuroAPI appoints mediator to help restructure pile of debt, shares drop

UPDATE 1-EuroAPI appoints mediator to help restructure pile of debt, shares drop Updates with market reaction segment By Nathan Vifflin June 7 (Reuters) - French pharmaceutical supplier EuroAPI EAPI.PA has engaged a third-party mediator, known as a mandataire ad hoc, to handle financing discussions with creditors as it struggles to serve a growing pile of debt.
S

Column: Will Zantac ruling make Delaware a mass torts magnet?

Column: Will Zantac ruling make Delaware a mass torts magnet? The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel June 3 (Reuters) - If you are mass torts lawyer, you should be paying attention to a trend that has emerged in litigation over the discontinued heartburn medication Zantac. On Friday, as my Reuters colleague Brendan Pierson reported , a Delaware Superior Court judge ruled that nearly 75,000 lawsuits alleging that Zantac causes cancer can mo
G
P
S

Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3

BRIEF-Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3 June 3 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: ASCO: SARCLISA IS FIRST ANTI-CD38 TO SIGNIFICANTLY IMPROVE PROGRESSION-FREE SURVIVAL IN COMBINATION WITH VRD FOR NEWLY DIAGNOSED TRANSPLANT-INELI
S

Investors prescribe harsh medicine for GSK’s boss

BREAKINGVIEWS-Investors prescribe harsh medicine for GSK’s boss The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to change ambiguous ‘them’ in fifth paragraph to ‘investors’. By Yawen Chen LONDON, June 3 (Reuters Breakingviews) - GSK GSK.L investors are having a panic attack. Jittery shareholders of the $93 billion British drugmaker on Monday wiped $9 billion off its value after a U.S.
A
G
S

Deutsche Post Group - Dhl Supply Chain Partners with Sanofi

BRIEF-Deutsche Post Group - Dhl Supply Chain Partners with Sanofi June 3 (Reuters) - DEUTSCHE POST AG DHLn.DE : DHL SUPPLY CHAIN EXPANDS PHARMA LOGISTICS OPERATIONS IN FRANCE DHL SUPPLY CHAIN HAS EXPANDED ITS SPECIALIZED LOGISTICS SERVICES FOR THE LIFE SCIENCES AND HEALTHCARE SECTOR IN FRANCE THROUGH A LONG-TERM STRATEGIC PARTNERSHIP WITH SANOFI DH
S

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed

UPDATE 2-GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed Updates shares and adds more analysts in paragraphs 7-11 By Yadarisa Shabong and Maggie Fick June 3 (Reuters) - Shares of GSK GSK.L dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.
G
P
S

Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT

BRIEF-Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT June 2 (Reuters) - SANOFI PUSHES AHEAD WITH €20BN CONSUMER HEALTHCARE SPIN-OFF - FT GOLDMAN SACHS, MORGAN STANLEY WILL WORK WITH BNP PARIBAS & BANK OF AMERICA ON SALE; POTENTIAL FLOAT EXPECTED TO TAKE PLACE AS SOON AS END OF YEAR - FT Source text: https://on.ft.com/4bXj
S

Delaware judge lets more than 70,000 Zantac lawsuits go forward

UPDATE 2-Delaware judge lets more than 70,000 Zantac lawsuits go forward Adds detail from opinion in paragraphs 3-4 By Brendan Pierson June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N
G
P
S

Delaware judge lets more than 70,000 Zantac lawsuits go forward

Delaware judge lets more than 70,000 Zantac lawsuits go forward June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, which had argued that the e
G
P
S

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review

UPDATE 1-EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review Adds details from EMA disclosure and background throughout May 31 (Reuters) - Sanofi SASY.PA and partner Regeneron Pharmaceuticals REGN.O have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review.
R
S

EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion

BRIEF-EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion May 31 (Reuters) - EMA: EMA SAYS IXCHIQ (CHIKUNGUNYA VACCINE (LIVE)) RECEIVED POSITIVE CHMP OPINION EMA:CHMP GAVE RECOMMENDATION FOR CONDITIONAL MARKETING AUTHORISATION FOR DURVEQTIX(FIDANACOGENE ELAPARVOVEC), GENE THERAPY TREATMENT FOR HAEMOPHILIA EMA SAYS CHMP HAS RESTART
P
S

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung' May 31 (Reuters) - French drugmaker Sanofi SASY.PA and its partner Regeneron REGN.O said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain patients 'smoker's lung', or COPD.
R
S

Sanofi: Dupixent Recommended For EU Approval By CHMP For Patients With COPD

BRIEF-Sanofi: Dupixent Recommended For EU Approval By CHMP For Patients With COPD May 31 (Reuters) - Sanofi SA SASY.PA : DUPIXENT RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT PATIENTS WITH COPD RECOMMENDATION FOR ADULTS WITH UNCONTROLLED COPD WITH RAISED BLOOD EOSINOPHILS BASED ON DATA FROM TWO LANDMARK PHASE 3 TRIALS EUROPEAN COMMISSION IS EXP
S

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch May 31 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. RENAULT RENA.PA The French automaker and Chinese peer Geely on Friday announced the creation of a 50-50 joint venture for hybrid and combustion powertrain components and systems.
R
R
S
T
V
F
N
U



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.